EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization

Wenxia Jiang, Alexander R Maldeney, Xue Yuan, Martin J Richer, Scott E Renshaw, Wei Luo

Cell Reports · 2024

DOI: 10.1016/j.celrep.2023.113665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Wenxia Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA vaccines have proven to be pivotal in the fight against COVID-19. A recommended booster, given 3 to 4 weeks post the initial vaccination, can substantially amplify protective antibody levels. Here, we show that, compared to contralateral boost, ipsilateral boost of the SARS-CoV-2 mRNA vaccine induces more germinal center B cells (GCBCs) specific to the receptor binding domain (RBD) and generates more bone marrow plasma cells. Ipsilateral boost can more rapidly generate high-affinity RBD-specific antibodies with improved cross-reactivity to the Omicron variant. Mechanistically, the ipsilateral boost promotes the positive selection and plasma cell differentiation of pre-existing GCBCs from the prior vaccination, associated with the expansion of T follicular helper cells. Furthermore, we show that ipsilateral immunization with an unrelated antigen after a prior mRNA vaccination enhances the germinal center and antibody responses to the new antigen compared to contralateral immunization. These findings propose feasible approaches to optimize vaccine effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19HumansSARS-CoV-2ImmunizationVaccinationRNA, MessengerAntibodies, ViralAntibodies, Neutralizing

Stichwörter der Autor:innen

CP: Immunologyantibodygerminal centermRNA vaccineplasma cell

Substanzen

COVID-19 VaccinesRNA, MessengerAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • Department of Otolaryngology - Head and Neck Surgery, School of Medicine, Indiana University, Indianapolis, IN 46202, USA; Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Ind…
  • Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, I…
  • Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Jiang, W., Maldeney, A. R., Yuan, X., Richer, M. J., Renshaw, S. E., & Luo, W. (2024). Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113665

Vancouver

Jiang W, Maldeney AR, Yuan X, Richer MJ, Renshaw SE, Luo W. Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization. Cell Reports. 2024. doi:10.1016/j.celrep.2023.113665

BibTeX
@article{Jiang2024,
  author = {Jiang, Wenxia and Maldeney, Alexander R and Yuan, Xue and Richer, Martin J and Renshaw, Scott E and Luo, Wei},
  title = {Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization},
  journal = {Cell Reports},
  year = {2024},
  doi = {10.1016/j.celrep.2023.113665}
}
Kostenlos starten →